2026-05-20T03:47:19Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/233762024-11-28T17:24:29Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16960col_20.500.12105_16967col_20.500.12105_16970

00925njm 22002777a 4500 dc Rey-Bua, Beatriz author Cabrero, Mónica author Bento, Leyre author Montoro, Juan author Bastos-Oreiro, Mariana author Parody, Rocio author Yanez, Lucrecia author Lopez-Godino, Oriana author Zanabili, Joud author Herrera, Pilar author Gutierrez, Gonzalo author Perez, Ariadna author Piñana, Jose L author Novelli, Silvana author Cortés, María author Sureda, Ana Maria author Caballero, Dolores author García-Sancho, Alejandro Martín author 2022-11-18 Background: Transformation of follicular lymphoma into an aggressive lymphoma (tFL) worsens the prognosis and the standard treatment is not completely defined. Allogeneic hematopoietic stem cell transplantation (alloSCT) could be a potentially curative option for these patients, but it has not been widely explored. Methods: We designed a retrospective multicenter study to analyze the efficacy and toxicity of alloSCT in tFL patients and potential prognostic factors of survival. Results: A total of 43 patients diagnosed with tFL who underwent alloSCT in 14 Spanish centers between January 2000 and January 2019 were included. Median age was 44 (31-67) years. After a median follow-up of 58 months, estimated 5-year overall survival (OS) and progression-free survival (PFS) were both 35%. Estimated 100-day and 1-year non-relapse mortality (NRM) were 20% and 34%, respectively. The type of conditioning regimen (3-year OS of 52% vs. 20%, respectively, for reduced-intensity vs. myeloablative conditioning) and development of chronic graft versus host disease (cGVHD) (3-year OS of 75% vs. 40%) were the only factors significantly associated with OS. The only variable with an independent association with OS was cGVHD (HR, 3.4; 95% CI, 1.2-9.6). Conclusions: Our results indicate that alloSCT continues to be a potentially curative option for patients with tFL. Rey-Búa B, Cabrero M, Bento L, Montoro J, Bastos-Oreiro M, Parody R, et al. Allogeneic Hematopoietic Stem Cell Transplantation in Transformed Follicular Lymphoma (tFL): Results of a Retrospective Multicenter Study from GELTAMO/GETH-TC Spanish Groups. Cancers (Basel). 2022 Nov 18;14(22):5670. 10.3390/cancers14225670 2072-6694 Cancers http://hdl.handle.net/20.500.13003/18685 36428762 L2020231296 2-s2.0-85142534780 https://hdl.handle.net/20.500.12105/23376 887056600001 Allogeneic Hematopoietic Stem Cell Transplantation in Transformed Follicular Lymphoma (tFL): Results of a Retrospective Multicenter Study from GELTAMO/GETH-TC Spanish Groups